In February, Sanofi CEO Paul Hudson reduce 4 high executives as a part of a bid to simplify the corporate’s administration construction. Amongst them was Ameet Nathwani, M.D., its chief medical officer and chief digital officer, who—like many a colleague earlier than him—made the leap from Massive Pharma to small biotech.
Nathwani takes the helm of Dewpoint Therapeutics from founding CEO Amir Nashat, who stays on as chair of the corporate’s board. The transfer comes simply weeks after Dewpoint closed a $77 million collection B spherical.
“Amir has deftly guided Dewpoint by two vital rounds of financing, assembled a powerful group, and helped craft an organization enthusiastic about understanding the function of condensates throughout illnesses,” Nathwani mentioned in an announcement. “I stay up for rising the corporate as we harness this cutting-edge science and the ability of our platforms to find and develop distinctive life-changing therapeutics.”
RELATED: Merck, Dewpoint unite to seek out HIV treatment in deal value as much as $305M
Dewpoint focuses on biomolecular condensates, membraneless organelles whose most important job is to encompass and include reactants—like proteins and nucleic acids—for chemical reactions inside cells. Researchers and drug builders have lengthy recognized about them, however condensates have been poorly understood and, so, untapped as drug targets.
Dewpoint constructed know-how to resolve that downside. Its high-throughput platform permits the corporate to check libraries of potential medication for particular results in condensates to seek out new methods of treating varied illnesses. The corporate is wanting into new therapies for most cancers, neurodegeneration, metabolic illness and immunology by itself and partnering with a pair of Massive Pharmas on HIV, coronary heart illness and ladies’s well being.
RELATED: Bayer, Dewpoint take purpose at coronary heart illness, ladies’s well being in deal value as much as $100M
“We’re thrilled to have a pacesetter with such an excellent file of getting new medication to sufferers as Dewpoint continues on its mission of translating the science of biomolecular condensates into much-needed medicines,” Nashat mentioned of his successor in an announcement on Tuesday.
That file comes from a long time at a number of Massive Pharma firms. Earlier than he joined Sanofi as chief medical officer in 2016, Nathwani held varied roles over 12 years at Novartis, ending up as international head of medical affairs. He has led the Swiss pharma’s important care enterprise, in addition to its cardiovascular and metabolism unit. Nathwani has led the event of greater than 20 medication, together with GlaxoSmithJline’s Coreg and Novartis’ Galvus, Diovan and Entresto.